Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia.

[2][4] No residual effects of the medication were observed 4 hours after daytime administration.

[2] It is a small-molecule compound and is structurally related to other clinically used orexin receptor antagonists.

[3] It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication.

[2][4] Side effects of seltorexant observed in clinical trials so far have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares.